Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25098955 | 1.00 | PKM (0.32) | PKMSMN1; SMN2ALDH1A1JAK2JAK1 | |
| SCHEMBL25098673 | 1.00 | PKM (0.32) | PKMSMN1; SMN2ALDH1A1JAK2JAK1 | |
| SCHEMBL25098672 | 0.88 | TP53 (0.32) | PKMSMN1; SMN2ALDH1A1TP53MDM2 | |
| SCHEMBL25098776 | 0.77 | ALDH1A1 (0.50) | PKMSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL25098444 | 0.77 | ALDH1A1 (0.50) | PKMSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL25099115 | 0.77 | ALDH1A1 (0.50) | PKMSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL2230808 | 0.73 | USP2 (0.35) | ALDH1A1TP53MDM2 | |
| SCHEMBL21028208 | 0.72 | PIK3CD (0.31) | ALDH1A1 | |
| SCHEMBL25099153 | 0.71 | PIK3CD (0.38) | SMN1; SMN2ALDH1A1JAK2 | |
| SCHEMBL24369250 | 0.71 | PIK3CD (0.38) | SMN1; SMN2ALDH1A1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | PKM 1202/4885SMN1; SMN2 3045/4885ALDH1A1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.